Xospata (gilteritinib) — Medica
Myeloid/Lymphoid Neoplasms with Eosinophilia and FLT3 rearrangement
Initial criteria
- Patient is age ≥ 18 years
- Patient has eosinophilia
- Disease is FLT3-mutation positive as detected by an approved test
Approval duration
1 year